Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease.
Saved in:
| Title: | Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease. |
|---|---|
| Authors: | Ghosh S; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States., Singh R; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States., Vanwinkle ZM; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States., McClain CJ; Department of Medicine, University of Louisville, Louisville, KY, United States.; Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, United States.; Hepatobiology & Toxicology Center, University of Louisville, Louisville, KY, United States.; Alcohol Research Center, University of Louisville, Louisville, KY, United States.; Robley Rex Louisville VAMC, Louisville, KY, United States.; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, United States., Vatsalya V; Department of Medicine, University of Louisville, Louisville, KY, United States.; Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, United States.; Alcohol Research Center, University of Louisville, Louisville, KY, United States.; Robley Rex Louisville VAMC, Louisville, KY, United States.; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, United States.; Clinical Laboratory for the Intervention Development of AUD and Organ Severity, University of Louisville, Louisville, KY, United States.; NIAAA, National Institutes of Health, Bethesda, MD, United States., Haribabu B; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States., Vemula PK; Institute for Stem Cell Biology and Regenerative Medicine (inStem), GKVK campus, Bangalore, Karnataka, India., Jala VR; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States.; Alcohol Research Center, University of Louisville, Louisville, KY, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2026 Jan 19; Vol. 16, pp. 1706111. Date of Electronic Publication: 2026 Jan 19 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2025.1706111 |
